Search clinical trials for: AK101 IV/AK101 SC

Total 354 results

Akeso

Completed

A Study of AK101 in Subjects With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

China
Akeso

Recruiting

A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Akeso

Recruiting

A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

China
Akeso

Recruiting

Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis

Plaque Psoriasis

China
Akeso

Completed

A Phase 3 Study of Efficacy and Safety of AK101 in Subjects With Psoriasis

Psoriasis Vulgaris

China
PMG Pharm Co., Ltd

Recruiting

A Phase 3 Study to Assess the Efficacy and Safety of PK101 in Patients With Knee Osteoarthritis

Knee Osteoarthritis

Korea, Republic of
PMG Pharm Co., Ltd

Completed

Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs

Arthritis

Korea, Republic of
Akeso

Recruiting

A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

China
Akeso

Recruiting

A Phase III Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis

Ankylosing Spondylitis

China
PMG Pharm Co., Ltd

Completed

Drug-Drug Interaction Between PK101-001 and PK101-002

Arthritis

Korea, Republic of
Akeso

Not yet recruiting

A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric and Gastroesophageal Junction Adenocarcinoma
Allakos Inc.

Completed

Study to Evaluate Multiple Doses in Patients With Nasal Polyposis

Nasal Polyposis

Belgium, United States, Germany, Netherlands, Spain, United Kingdom
Akeso
Akeso Tiancheng, Inc

Completed

Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Akeso

Recruiting

To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis

Skin Diseases | Psoriasis

China
Aimmune Therapeutics, Inc.

Terminated

Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

Peanut Allergy

Spain
Akeso

Not yet recruiting

A Phase II Study of AK104 for Recurrent or Metastatic Vulvar Cancer

Vulvar Cancer

China
Akeso

Not yet recruiting

AK104 in Neoadjuvant Treatment of Cervical Cancer

Cervical Cancer

China
Ayala Pharmaceuticals, Inc,

Terminated

A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer (TENACITY)

Triple Negative Breast Cancer

United States, Belgium, Israel, Spain, United Kingdom
Aimmune Therapeutics, Inc.

Completed

PALISADE Follow-on Study (ARC004)

Peanut Allergy

United States, Spain, Netherlands, Italy, Canada, Germany, Ireland, Sweden, United Kingdom
Second Affiliated Hospital of Zunyi Medical University
Guizhou Provincial People's Hospital; The First People's Hospital of Zunyi; Guizhou... and other collaborators

Recruiting

Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC

Immunotherapy | Second-line Treatment

China
Wuhan Union Hospital, China

Recruiting

Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Akeso

Not yet recruiting

A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

Hepatocellular Carcinoma

China
Akeso

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis

Skin Diseases | Psoriasis

China
Akeso

Active, not recruiting

A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors

Advanced or Metastatic Solid Tumors

Australia
Akeso

Active, not recruiting

A Trial of AK104 Plus Anlotinib in NSCLC

NSCLC

China
Aimmune Therapeutics, Inc.

Completed

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) (RAMSES)

Peanut Allergy

United States, Canada
Beijing Likang Life Science and Tech Co., Ltd.

Recruiting

Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors

Advanced Solid Tumor

China
Chinese PLA General Hospital

Not yet recruiting

A Study of Combination Therapy in NSCLC

Non-small Cell Lung Cancer
Akeso

Completed

A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis

Psoriasis

China
Akeso
AD Pharmaceuticals Co., Ltd.

Completed

A Study of PCSK9 Inhibitor AK102 in Healthy Subjects

Hypercholesterolaemia

China
Akeso
Akeso Tiancheng, Inc

Completed

A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Aimmune Therapeutics, Inc.

Completed

AR101 Real-World Open-Label Extension Study

Peanut Allergy

United States, Canada
Ayala Pharmaceuticals, Inc,

Completed

A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations (ACCURACY)

Adenoid Cystic Carcinoma

United States, Canada, France, United Kingdom, Israel, Netherlands
Akesobio Australia Pty Ltd

Completed

A Study of AK111 in Healthy Subjects

Psoriasis

New Zealand
Shengjing Hospital

Not yet recruiting

Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Shanxi Province Cancer Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

Urothelial Carcinoma

China
Tianjin Medical University Cancer Institute and...

Enrolling by invitation

Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma

Recurrent/Refractory Classical Hodgkin's Lymphoma

China
Akesobio Australia Pty Ltd

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours

Advanced or Metastatic Solid Tumours

Australia
M.D. Anderson Cancer Center

Active, not recruiting

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

Cervical Cancer | Cervix Cancer | Carcinomas

United States
Akeso

Completed

A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Active Ankylosing Spondylitis

Ankylosing Spondylitis

China
Akeso

Completed

A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis

Psoriasis

China
Chongqing University Cancer Hospital
Akeso Pharmaceuticals, Inc.

Recruiting

Study Of Candonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer

Locally Advanced Cervical Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours

Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy

China
Tianjin Medical University Cancer Institute and...

Recruiting

A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy

China
Asahi Kasei Pharma Corporation

Completed

A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Poland, Ukraine, Germany, Hungary, United Kingdom, Slovakia, Czech Republic
Akeso

Completed

A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects

Healthy Male Subjects

China
Akeso

Recruiting

A Study of AK131 in Patients With Advanced Solid Tumors

Solid Tumor

China
Peking Union Medical College Hospital

Recruiting

Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003 (ALTER-C003)

Colorectal Cancer

China
Peking University

Not yet recruiting

AK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer

MSI-H/dMMR Gastric Carcinoma and Colorectal Cancer
Akeso
Akeso Tiancheng, Inc

Active, not recruiting

A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China

3

Subscribe